Study of anlotinib and benmelstobart for advanced thyroid cancer
Part of Cancer, Hormones & metabolism clinical trials.
This trial tests a combination of two drugs, anlotinib (a targeted therapy) and benmelstobart (an immunotherapy), for people with differentiated thyroid cancer that has spread or cannot be removed. It may be an option if your cancer did not respond to or got worse after first treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with a type of thyroid cancer called differentiated thyroid cancer.
- Your cancer cannot be removed by surgery or has spread to other parts of the body.
- Your cancer did not shrink or came back after your first treatment.
- You have at least one tumor that can be measured on scans.
- You are 18 years or older.
- You agree to have a biopsy of your tumor (a small sample taken) when you join the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a targeted therapy pill (anlotinib) for people with advanced thyroid cancer that stopped responding to radioactive iodine. It may slow tumor growth or shrink tumors.
This trial studies anlotinib in people with advanced or metastatic medullary thyroid cancer that has been getting worse. It aims to see how well the treatment controls the cancer and how safe it is for patients who can’t have curative surgery.
This trial tests a combination of two drugs (anlotinib and benmelstobart) as a first treatment for people with advanced esophageal squamous cell carcinoma that cannot be removed by surgery or has spread. The goal is to see if this combination helps control the cancer.
This trial tests a combination of two drugs (anlotinib, a targeted therapy, and benmelstobart, an immunotherapy) for people with advanced pheochromocytoma or paraganglioma that cannot be removed by surgery. The goal is to see if this new combination can shrink tumors or stop them from growing when other treatments are not an option.
This trial tests whether giving targeted drugs before surgery can shrink advanced thyroid cancers that are hard to remove. It uses genetic test results to match you to a specific treatment arm, aiming to make surgery safer and more successful.
This trial tests if an existing drug (used for other conditions) can help people with advanced thyroid cancer who have run out of treatment options. You'll get a new drug and be monitored to see if it shrinks your cancer or slows it down.
Hear when a new Thyroid Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.